F. Saghafifar

Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications

B. Barlogie, L. Fink, R. Desikan, 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes.

B. Barlogie, E. Anaissie, G. Tricot, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The blood coagulation mechanism in multiple myeloma.

B. Barlogie, L. Fink, G. Tricot, 2003, Seminars in thrombosis and hemostasis.

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

Bart Barlogie, Louis Fink, Joth Jacobson, 2004, British journal of haematology.

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.

B. Barlogie, L. Fink, E. Anaissie, 2002, Blood.

18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer.

B. Barlogie, E. Anaissie, G. Tricot, 2004 .